An individual reference limit of the serum CEA–TPA–CA 15-3 tumor marker panel in the surveillance of asymptomatic women following surgery for primary breast cancer

References

• DuffyMJMcDermottEWCrownJBlood-based biomarkers in breast cancer: from proteins to circulating tumor cells to circulating tumor DNATumour Biol2018405101042831877616
   Google Scholar
• No authors listedClinical practice guidelines for the use of tumor markers in breast and colorectal cancerJ Clin Oncol199614284328778874347
   PubMed Web of Science ®Google Scholar
• BastRCRavdinPHayesDFAmerican Society of Clinical Oncology Tumor Markers Expert Panel2000 Update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical OncologyJ Clin Oncol20011961865187811251019
   PubMed Web of Science ®Google Scholar
• HarrisLFritscheHMennelRAmerican Society of Clinical OncologyAmerican Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancerJ Clin Oncol200725335287531217954709
   PubMed Web of Science ®Google Scholar
• SenkusEKyriakidesSOhnoSESMO Guidelines CommitteePrimary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnn Oncol201526Suppl 5v8v3026314782
   PubMed Web of Science ®Google Scholar
• RamseySDHenryNLGralowJRTumor marker usage and medical care costs among older early-stage breast cancer survivorsJ Clin Oncol201533214915525332254
   PubMed Web of Science ®Google Scholar
• KeatingNLLandrumMBGuadagnoliEWinerEPAyanianJZSurveillance testing among survivors of early-stage breast cancerJ Clin Oncol20072591074108117369571
   PubMed Web of Science ®Google Scholar
• HahnEEHaysRDKahnKLLitwinMSGanzPAUse of imaging and biomarker tests for posttreatment care of early-stage breast cancer survivorsCancer2013119244316432424105101
   PubMed Web of Science ®Google Scholar
• DnistrianAMSchwartzMKGreenbergEJSmithCASchwartzDCCA 15-3 and carcinoembryonic antigen in the clinical evaluation of breast cancerClin Chim Acta19912002–381931777973
   PubMed Web of Science ®Google Scholar
• GuadagniFFerroniPCarliniSA re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: a prospective longitudinal studyClin Cancer Res2001782357236211489813
   PubMed Web of Science ®Google Scholar
• MarianiLMiceliRMichilinSGionMSerial determination of CEA and CA 15.3 in breast cancer follow-up: an assessment of their diagnostic accuracy for the detection of tumour recurrencesBiomarkers200914213013619330591
   PubMed Web of Science ®Google Scholar
• MolinaRZanónGFilellaXUse of serial carcinoembryonic antigen and CA 15.3 assays in detecting relapses in breast cancer patientsBreast Cancer Res Treat199536141487579505
   PubMed Web of Science ®Google Scholar
• StieberPNagelDBlankenburgIDiagnostic efficacy of CA 15-3 and CEA in the early detection of metastatic breast cancer – a retrospective analysis of kinetics on 743 breast cancer patientsClin Chim Acta201544822823126160053
   PubMed Web of Science ®Google Scholar
• di GioiaDBlankenburgINagelDHeinemannVStieberPTumor markers in the early detection of tumor recurrence in breast cancer patients: CA 125, CYFRA 21-1, HER2 shed antigen, LDH and CRP in combination with CEA and CA 15-3Clin Chim Acta20164611727451906
   PubMed Web of Science ®Google Scholar
• NicoliniAFerrariPFulceriFCarpiARossiGAn individual reference limit for ‘early’ diagnosis of metastatic breast cancer during postoperative follow-upBiomark Med20159430731725808435
   PubMed Web of Science ®Google Scholar
• NicoliniATartarelliGCarpiAIntensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastasesBMC Cancer2006626917116247
   PubMed Web of Science ®Google Scholar
• NicoliniAFerrariPSagripantiACarpiAThe role of tumour markers in predicting skeletal metastases in breast cancer patients with equivocal bone scintigraphyBr J Cancer1999799–101443144710188888
   PubMed Web of Science ®Google Scholar
• NicoliniACarpiAFerrariPThe role of tumour markers in improving the accuracy of conventional chest X-ray and liver echography in the post-operative detection of thoracic and liver metastases from breast cancerBr J Cancer200083111412141711076646
   PubMed Web of Science ®Google Scholar
• HojoTMasudaNMizutaniTIntensive vs. standard postoperative surveillance in high-risk breast cancer patients (INSPIRE): Japan Clinical Oncology Group Study JCOG1204Jpn J Clin Oncol2015451098398626246481
   PubMed Web of Science ®Google Scholar
• No authors listedImpact of follow-up testing on survival and health-related quality of life in breast cancer patients. A multicenter randomised controlled trial. The Givio InvestigatorsJAMA1994271158715928182811
   PubMed Web of Science ®Google Scholar
• Rosselli del TurcoMPalliDCariddiACiattoSPaciniPDistanteVIntensive diagnostic follow-up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer follow-upJAMA199427120159315977848404
   PubMed Web of Science ®Google Scholar
• HarbeckNGnantMBreast cancerLancet2017389100741134115027865536
   PubMed Web of Science ®Google Scholar
• KaklamaniVGGradisharWJEndocrine therapy in the current management of postmenopausal estrogen receptor-positive metastatic breast cancerOncologist201722550751728314835
   PubMed Web of Science ®Google Scholar
• GingrasIGebhartGde AzambujaEPiccart-GebhartMHER2-positive breast cancer is lost in translation: time for patient-centered researchNat Rev Clin Oncol2017141166968128762384
   PubMed Web of Science ®Google Scholar
• NixonNAHannoufMBVermaSA review of the value of human epidermal growth factor receptor 2 (HER2)-targeted therapies in breast cancerEur J Cancer201889728129241083
   PubMed Web of Science ®Google Scholar
• de GrootAFKuijpersCJKroepJRCDK4/6 inhibition in early and metastatic breast cancer: a reviewCancer Treat Rev20176013013828961554
   PubMed Web of Science ®Google Scholar